Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial (Q43261590)

17 November 2017

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial (English)

1 reference

17 November 2017

1 reference

1 reference

1 reference

head and neck carcinoma

1 reference

Fernando Rivera

1

1 reference

17 November 2017

Almudena García-Castaño

2

1 reference

17 November 2017

Noelia Vega

3

1 reference

17 November 2017

Maria Eugenia Vega-Villegas

4

1 reference

17 November 2017

Lourdes Gutiérrez-Sanz

5

1 reference

17 November 2017

language of work or name

1 reference

1 October 2009

1 reference

Expert Review of Anticancer Therapy

17 November 2017

1 reference

17 November 2017

9

1 reference

17 November 2017

10

1 reference

17 November 2017

1421-1428

1 reference

The protein tyrosine kinase family of the human genome

17 November 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Role of an anti-epidermal growth factor receptor in treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Expanding role of the medical oncologist in the management of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.113

21 January 2018

Identifiers

DOI

10.1586/ERA.09.113

1 reference

17 November 2017

1 reference